The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.
Mary L. Disis
No relevant relationships to disclose
Andrew L. Coveler
No relevant relationships to disclose
Doreen Higgins
No relevant relationships to disclose
Patricia Fintak
No relevant relationships to disclose
James Ross Waisman
No relevant relationships to disclose
Jessica Reichow
No relevant relationships to disclose
Meredith Slota
No relevant relationships to disclose
Jennifer Childs
No relevant relationships to disclose
Yushe Dang
No relevant relationships to disclose
Lupe G. Salazar
No relevant relationships to disclose